First Patient Dosed in Phase III ProstACT GLOBAL Study of ...
Telix's Group Chief Medical Officer, Dr Colin Hayward, highlights the milestone of dosing the first patient in the ProstACT GLOBAL study, emphasizing its potential to enhance data on TLX591. This study explores a first-in-class rADC candidate's benefits with standard care, thanking the clinical team and participating patients.
Reference News
First Patient Dosed in Phase III ProstACT GLOBAL Study of ...
Telix's Group Chief Medical Officer, Dr Colin Hayward, highlights the milestone of dosing the first patient in the ProstACT GLOBAL study, emphasizing its potential to enhance data on TLX591. This study explores a first-in-class rADC candidate's benefits with standard care, thanking the clinical team and participating patients.